Abstract 1058P
Background
Malignant ascites occur in 10 – 15% of patients with cancers from gastrointestinal tract, and it leads to impaired quality of life and declined performance. The abundance of immune cells in the peritoneum and ascites, as well as the immune escaped circumstance created by cancer cells in the peritoneum, suggest the potential use of intraperitoneal (IP) immune checkpoint inhibitors to control malignant ascites.
Methods
Patients with cancers from gastrointestinal or pancreaticobiliary tract who had cytologically confirmed malignant ascites were enrolled. Twenty mg of nivolumab diluted in 100 ml of saline was infused into the peritoneal cavity in 10 minutes after paracentesis. IP therapy was repeated after each paracentesis until ineffectiveness of therapy judged by physician, unacceptable toxicity, or patient’s refusal. The clinical response and adverse effects were recorded. The cellular components of malignant ascites sampled prior each paracentesis were analyzed by flow cytometry.
Results
Totally, 9 patients with a median age of 55 years were treated with IP nivolumab. The cancer types were pancreatic cancer in 4, biliary tract cancer in 3, and gastric cancer in 2 patients. Systemic anticancer treatments were given for 3 lines in 2, 2 lines in 2, and 1 line in 4 patients before the administration of IP nivolumab. After a median of 3 (2 – 5) cycles of treatment, 7 (77%) patients had clinical response as evidenced by reduced ascites and less frequent paracentesis. The change of tumor cell number in serial ascites, instead of the change of lymphocyte counts and lymphocyte percentage, correlated with the clinical response. There was only grade 1 tenderness over the puncture site as the adverse effect. The reasons of stop IP were death due to disease progression in 5, patient’s wish in 2, and clinical unresponsiveness in 2 patients, respectively.
Conclusions
IP administration of nivolumab was a safe and effective method to control malignant ascites from gastrointestinal or pancreaticobiliary tract cancer. Further validation of the application in larger population and other types of cancer, as well as biomarkers study are needed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The National Health Research Institutes, Taiwan (NHRI-112A1-CACO-13232302) China Medical University Hospital (DMR-112-195) Ministry of Science and Technology, Taiwan (MOST110-2314-B-039-034-MY3).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1079TiP - A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Presenter: Shiraj Sen
Session: Poster session 19
1080TiP - An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)
Presenter: Vladimir Galvao
Session: Poster session 19
1325P - Sunvozertinib as first-line treatment in NSCLC patients with EGFR Exon20 insertion mutations
Presenter: James Chih-Hsin Yang
Session: Poster session 19
1326P - Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Presenter: David Planchard
Session: Poster session 19
1327P - First-line osimertinib in patients with EGFR mutated lung cancer with uncommon mutations (OCELOT study – interim analysis)
Presenter: Daniel Breadner
Session: Poster session 19
1328P - Analysis of data from the AENEAS study assessing the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), aumolertinib, and virtual comparison with osimertinib
Presenter: Meredith LaRose
Session: Poster session 19
1329P - FIND: A phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC
Presenter: Lucia Nogova
Session: Poster session 19
1330P - Updated results of the efficacy and safety of KN046 (a bispecific anti-PD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer (NSCLC) who failed prior EGFR-TKI(s)
Presenter: Caicun Zhou
Session: Poster session 19